MARKET

SABS

SABS

SAB BIOTHERAPEUTICS INC
NASDAQ
4.230
+0.060
+1.44%
After Hours: 4.220 -0.01 -0.24% 18:02 02/09 EST
OPEN
4.220
PREV CLOSE
4.170
HIGH
4.295
LOW
4.040
VOLUME
246.18K
TURNOVER
--
52 WEEK HIGH
6.60
52 WEEK LOW
1.000
MARKET CAP
201.38M
P/E (TTM)
-1.5079
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SABS last week (0202-0206)?
Weekly Report · 22h ago
SAB Biotherapeutics to Present at Guggenheim Biotech Summit and Oppenheimer Healthcare Conference
Reuters · 5d ago
Weekly Report: what happened at SABS last week (0126-0130)?
Weekly Report · 02/02 09:51
Weekly Report: what happened at SABS last week (0119-0123)?
Weekly Report · 01/26 09:51
Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks
TipRanks · 01/24 11:05
Weekly Report: what happened at SABS last week (0112-0116)?
Weekly Report · 01/19 09:55
SAB Biotherapeutics Updates SAB-142 Roadmap and Funding Outlook
TipRanks · 01/12 22:20
Weekly Report: what happened at SABS last week (0105-0109)?
Weekly Report · 01/12 09:54
More
About SABS
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.

Webull offers SAB Biotherapeutics Inc stock information, including NASDAQ: SABS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SABS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SABS stock methods without spending real money on the virtual paper trading platform.